Phathom Pharmaceuticals, Inc.
PHATNext catalyst
Vonoprazan
Non-Erosive Gastro-Esophageal Reflux Disease
Get an email about PHAT's next catalysts
Track Phathom Pharmaceuticals (PHAT) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (Phase 3 readout).See the timeline
2 upcoming, 1 past
Vonoprazan Phase 2 Est. Readout
Primary completion for Vonoprazan trial (NCT06851559) in Eosinophilic Esophagitis
SourceVonoprazan Phase 3 Est. Readout
Estimated primary completion for Vonoprazan trial (NCT07752407) in Symptomatic Non-erosive Gastroesophageal Reflux Disease. Topline data typically follows completion by weeks to months.
SourceHow PHAT's past catalysts played out
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Lansoprazole | Phase 3 | Erosive Esophagitis | - | - |
Vonoprazan | Phase 3 | Non-Erosive Gastro-Esophageal Reflux Disease | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Phathom Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Phathom Pharmaceuticals, Inc.'s (PHAT) pipeline across Phase 3. Its lead program is Vonoprazan (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Phathom Pharmaceuticals, Inc.'s next FDA catalyst?→
Phathom Pharmaceuticals, Inc.'s (PHAT) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PHAT biotech catalysts?→
Add PHAT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Phathom Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.